BMS Pravachol REGRESS study shows slowing of coronary atherosclerosis progression.

Executive Summary

BRISTOL PRAVACHOL TRIAL FINDS SLOWING OF CORONARY ATHEROSCEROSIS progression beginning within six months of therapy with the Bristol-Myers Squibb cholesterol-lowering drug pravastatin, as well as a reduction in clinical events at the end of two years. Results of the 885-patient Regression Growth Evaluation Statin Study (REGRESS), which enrolled men with mild to moderately elevated cholesterol levels, were presented March 21 at the annual meeting of the American College of Cardiology in New Orleans.